This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Small-Cap Winners & Losers

The small-cap sector mimicked the choppy broad indices and traded little changed Thursday, despite some big moves among individual names.

General Steel (GSI - Get Report) was one of the biggest winners, surging some 50% to $14.25 after getting listed on the American Stock Exchange. The China-based steel concern previously traded on the OTC bulletin board.

Another China-based company, Orsus Xelent Technologies (ORS), shot up 52% to $4.93 after projecting a year-over-year sales increase of more than 20% in the third quarter. That would mean a top line in excess of $24.6 million for the cell-phone designer.

California's Hollis-Eden Pharmaceuticals (HEPH) surged 24% after saying its HE3235 cancer treatment " significantly inhibited tumor growth " in preclinical testing on hormone-independent tumors, which are associated with late-stage prostate cancer. Hollis shares were trading at $2.53.

But fellow health-care stock Bioject Medical Technologies (BJCT) plunged 23.4% on word Roche and Trimeris (TRMS) will no longer pursue regulatory approval to use the company's Biojector 2000 with their anti-HIV drug Fuzeon.

Shares of Bioject, Portland, Ore., fell 33 cents to $1.08. Trimeris was recently off 4.8%.

Charlotte Russe (CHIC), a San Diego-based women's apparel retailer, sank 10.5% after JPMorgan downgraded the stock in light of Wet Seal's (WTSLA) third-quarter profit warning Wednesday night. The analyst said that Wet Seal, a teen-girls' apparel chain, was probably hurt by broad factors such as "tough mall traffic and warmer weather."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs